BioSpectrum Asia - April 2024

In dieser Angelegenheit

Addressing Accessibility and Affordability of CELL & GENE THERAPIES
Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry. Quite a few companies in the field are making remarkable advancements toward potentially curative treatments for challenging diseases using groundbreaking science. With lower R&D development costs than in advanced markets, China is becoming an attractive market for the development of CGT, and therefore may emerge as a strong competitor of overseas-made CGT, notes a
GlobalData report. Bayer AG, recently announced the global expansion of its life science incubator network, Bayer Co. Lab, to Shanghai, China and Kobe, Japan. The new site in China will focus on oncology and CGT innovations. While India lags behind China in the production of cell and gene therapies, a wave of new biotech startups is emerging to address this challenge. Immuneel Therapeutics and ImmunoACT are currently developing CAR-T cell therapies. The latter’s NexCAR19 therapy received approval from India's Central Drug Standards Control organisation (CDSCO) for treating relapsed or refractory B-cell lymphomas and leukaemia. Despite a steady stream of regulatory approvals and promising growth prospects, the high manufacturing costs associated with these therapies often render them inaccessible to the majority of patients. To address this issue, companies are actively striving to streamline and optimise the highly intricate and labour-intensive process of cell and gene therapy manufacturing.

Addressing Accessibility and Affordability of CELL & GENE THERAPIES

Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry.

10+ mins

"We anticipate India will adopt decentralised models for managing CGTs, ensuring closer proximity between patients and treatment facilities"

Cell and gene therapy (CGT) expert from Germany, Miltenyi Biotec has recently announced its entry into the Indian market to provide researchers, scientists and clinicians easier access to expertise, research, and manufacturing solutions.

5 mins

Addressing Challenges in Cell Therapy Manufacturing

Even with significant advancements, there are still anumber of issues with cell therapy manufacturing that need to be resolved as production grows.

2 mins

Engineering CAR T cell sharpshooters

Approved CAR T-cell therapies have shown remarkable results in patients with certain types of blood cancers.

6 mins

Can Test, Treat, Track Beat Malaria?

Malaria has long been a major public health concern in the Asia Pacific region, particularly in South East Asia (SEA) affecting millions of people.

8 mins

"Because of its specificity and selectivity, ADCS have the potential to reduce adverse side effects and improve patient survival"

Japan-headquartered Daiichi Sankyo, the global healthcare company, launched its subsidiary Daiichi Sankyo Singapore Pte. Ltd. to bridge unmet needs in oncology.

4 mins

"AI will be integrally involved in not only the diagnosis of cancer but also in determining the prognosis and best therapeutic option”

South Korea-based Deep Bio, a pioneering artificial intelligence (AI) healthcare firm focused on cancer pathology, is making waves in the industry.

5 mins

How Indian Biotech Investments are on a Doubling Spree

A latest report by Ankur Capital provides a closer look at the investments made in biotechnology in the last decade in the country.

4 mins

Lesen Sie alle Geschichten von BioSpectrum Asia

BioSpectrum Asia Magazine Description:

BioSpectrum Asia Magazine is a monthly magazine published by MM Activ Sci-Tech Communication in India. It is a leading biotechnology magazine in Asia, covering a wide range of topics related to the biotechnology industry, including:

* Biotechnology news and trends: BioSpectrum Asia covers the latest biotechnology news and trends from India and around the world.
* Biotechnology company profiles and interviews: The magazine profiles leading biotechnology companies in Asia and interviews their CEOs and other top executives.
* Biotechnology research and development: BioSpectrum Asia covers the latest biotechnology research and development from academic institutions and pharmaceutical companies.
* Biotechnology product reviews: The magazine reviews the latest biotechnology products and services.
* Biotechnology industry events: BioSpectrum Asia covers biotechnology industry events from around the world.

BioSpectrum Asia Magazine is a must-read for anyone who wants to stay informed about the latest advances in biotechnology and their potential to impact the world around us.